ESC 2024: Findings from the FINEARTS-HF clinical trial provide the first definite evidence that an MRA can be beneficial in patients with HFmrEF/HFpEF.
Finerenone treatment achieved a statistically significant reduction in a composite endpoint of CV death and HF events in a population not limited to CKD in T2D, Bayer announced.
Tirzepatide reduced the risk of severe heart failure outcomes by 38% and drove weight loss of 15.7% in adults with HFpEF and obesity, with and without T2D..
Between 2000 and 2022, there were nearly 800 000 excess CV deaths among Black Americans and 24 million additional years of life lost, researchers report.